[4]
Complementary assets, strategic alliances, and the incumbent’s advantage: an empirical study of industry and firm effects in the biopharmaceutical industry[J] . Frank T Rothaermel.Research Policy . 2001 (8)
[4]
Complementary assets, strategic alliances, and the incumbent’s advantage: an empirical study of industry and firm effects in the biopharmaceutical industry[J] . Frank T Rothaermel.Research Policy . 2001 (8)